[EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY [FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
[EN] INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH [FR] INHIBITEURS DE L'ACTIVITÉ DÉSHYDROGÉNASE À CHAÎNE COURTE POUR FAVORISER LA NEUROGENÈSE ET INHIBER LA MORT DES CELLULES NERVEUSES
[EN] INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS<br/>[FR] INHIBITEURS DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE POUR LE TRAITEMENT DE LA FIBROSE
申请人:UNIV CASE WESTERN RESERVE
公开号:WO2016144958A1
公开(公告)日:2016-09-15
A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.
Compositions and methods of modulating short-chain dehydrogenase activity
申请人:CASE WESTERN RESERVE UNIVERSITY
公开号:US10869871B2
公开(公告)日:2020-12-22
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
Inhibitors of short-chain dehydrogenase activity for treating fibrosis
申请人:CASE WESTERN RESERVE UNIVERSITY
公开号:US10945998B2
公开(公告)日:2021-03-16
A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair
作者:Monika I. Antczak、Yongyou Zhang、Changguang Wang、Jennifer Doran、Jacinth Naidoo、Sukesh Voruganti、Noelle S. Williams、Sanford D. Markowitz、Joseph M. Ready
DOI:10.1021/acs.jmedchem.7b00271
日期:2017.5.11
The enzyme 15-prostaglandin dehydrogenase (15-PGDH) catalyzes the first step in the degradation of prostaglandins including PGE2. It is a negative regulator of tissue repair and regeneration in multiple organs. Accordingly, inhibitors of 15-PGDH are anticipated to elevate in vivo levels of PGE2 and to promote healing and tissue regeneration. The small molecule SW033291 (1) inhibits 15-PGDH with K-i = 0.1 nM in vitro, doubles PGE2 levels in vivo, and shows efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy. Here we describe optimized variants of 1 with improved solubility, druglike properties, and in vivo activity.
COMPOSITIONS COMPRISING A 15-PGDH INHIBITOR FOR THE HEALING OF WOUNDS